Cargando…

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Saruta, Masayuki, Park, Dong Il, Kim, Young-Ho, Yang, Suk-Kyun, Jang, Byung-Ik, Cheon, Jae Hee, Im, Jong Pil, Kanai, Takanori, Katsuno, Tatsuro, Ishiguro, Yoh, Nagaoka, Makoto, Isogawa, Naoki, Li, Yinhua, Banerjee, Anindita, Ahmad, Alaa, Hassan-Zahraee, Mina, Clare, Robert, Gorelick, Kenneth J., Cataldi, Fabio, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000638/
https://www.ncbi.nlm.nih.gov/pubmed/32013314
http://dx.doi.org/10.5217/ir.2019.00039
_version_ 1783494075644641280
author Saruta, Masayuki
Park, Dong Il
Kim, Young-Ho
Yang, Suk-Kyun
Jang, Byung-Ik
Cheon, Jae Hee
Im, Jong Pil
Kanai, Takanori
Katsuno, Tatsuro
Ishiguro, Yoh
Nagaoka, Makoto
Isogawa, Naoki
Li, Yinhua
Banerjee, Anindita
Ahmad, Alaa
Hassan-Zahraee, Mina
Clare, Robert
Gorelick, Kenneth J.
Cataldi, Fabio
Watanabe, Mamoru
Hibi, Toshifumi
author_facet Saruta, Masayuki
Park, Dong Il
Kim, Young-Ho
Yang, Suk-Kyun
Jang, Byung-Ik
Cheon, Jae Hee
Im, Jong Pil
Kanai, Takanori
Katsuno, Tatsuro
Ishiguro, Yoh
Nagaoka, Makoto
Isogawa, Naoki
Li, Yinhua
Banerjee, Anindita
Ahmad, Alaa
Hassan-Zahraee, Mina
Clare, Robert
Gorelick, Kenneth J.
Cataldi, Fabio
Watanabe, Mamoru
Hibi, Toshifumi
author_sort Saruta, Masayuki
collection PubMed
description BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD). METHODS: OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients. RESULTS: In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7(+) central memory CD4(+) T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment. CONCLUSIONS: In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509)
format Online
Article
Text
id pubmed-7000638
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Association for the Study of Intestinal Diseases
record_format MEDLINE/PubMed
spelling pubmed-70006382020-02-12 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study Saruta, Masayuki Park, Dong Il Kim, Young-Ho Yang, Suk-Kyun Jang, Byung-Ik Cheon, Jae Hee Im, Jong Pil Kanai, Takanori Katsuno, Tatsuro Ishiguro, Yoh Nagaoka, Makoto Isogawa, Naoki Li, Yinhua Banerjee, Anindita Ahmad, Alaa Hassan-Zahraee, Mina Clare, Robert Gorelick, Kenneth J. Cataldi, Fabio Watanabe, Mamoru Hibi, Toshifumi Intest Res Original Article BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD). METHODS: OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients. RESULTS: In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7(+) central memory CD4(+) T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment. CONCLUSIONS: In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509) Korean Association for the Study of Intestinal Diseases 2020-01 2020-01-30 /pmc/articles/PMC7000638/ /pubmed/32013314 http://dx.doi.org/10.5217/ir.2019.00039 Text en © Copyright 2020. Korean Association for the Study of Intestinal Diseases. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Saruta, Masayuki
Park, Dong Il
Kim, Young-Ho
Yang, Suk-Kyun
Jang, Byung-Ik
Cheon, Jae Hee
Im, Jong Pil
Kanai, Takanori
Katsuno, Tatsuro
Ishiguro, Yoh
Nagaoka, Makoto
Isogawa, Naoki
Li, Yinhua
Banerjee, Anindita
Ahmad, Alaa
Hassan-Zahraee, Mina
Clare, Robert
Gorelick, Kenneth J.
Cataldi, Fabio
Watanabe, Mamoru
Hibi, Toshifumi
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title_full Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title_fullStr Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title_full_unstemmed Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title_short Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
title_sort anti-madcam-1 antibody (pf-00547659) for active refractory crohn’s disease in japanese and korean patients: the opera study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000638/
https://www.ncbi.nlm.nih.gov/pubmed/32013314
http://dx.doi.org/10.5217/ir.2019.00039
work_keys_str_mv AT sarutamasayuki antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT parkdongil antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT kimyoungho antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT yangsukkyun antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT jangbyungik antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT cheonjaehee antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT imjongpil antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT kanaitakanori antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT katsunotatsuro antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT ishiguroyoh antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT nagaokamakoto antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT isogawanaoki antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT liyinhua antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT banerjeeanindita antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT ahmadalaa antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT hassanzahraeemina antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT clarerobert antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT gorelickkennethj antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT cataldifabio antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT watanabemamoru antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy
AT hibitoshifumi antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy